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A BS TR AC T
BACKGROUND
Suppression of ovarian estrogen production reduces the recurrence of hormone-
receptor–positive early breast cancer in premenopausal women, but its value when 
added to tamoxifen is uncertain.
METHODS
We randomly assigned 3066 premenopausal women, stratified according to prior 
receipt or nonreceipt of chemotherapy, to receive 5 years of tamoxifen, tamoxifen 
plus ovarian suppression, or exemestane plus ovarian suppression. The primary 
analysis tested the hypothesis that tamoxifen plus ovarian suppression would im-
prove disease-free survival, as compared with tamoxifen alone. In the primary 
analysis, 46.7% of the patients had not received chemotherapy previously, and 
53.3% had received chemotherapy and remained premenopausal.
RESULTS
After a median follow-up of 67 months, the estimated disease-free survival rate at 
5 years was 86.6% in the tamoxifen–ovarian suppression group and 84.7% in the 
tamoxifen group (hazard ratio for disease recurrence, second invasive cancer, or death, 
0.83; 95% confidence interval [CI], 0.66 to 1.04; P = 0.10). Multivariable allowance 
for prognostic factors suggested a greater treatment effect with tamoxifen plus 
ovarian suppression than with tamoxifen alone (hazard ratio, 0.78; 95% CI, 0.62 to 
0.98). Most recurrences occurred in patients who had received prior chemotherapy, 
among whom the rate of freedom from breast cancer at 5 years was 82.5% in the 
tamoxifen–ovarian suppression group and 78.0% in the tamoxifen group (hazard 
ratio for recurrence, 0.78; 95% CI, 0.60 to 1.02). At 5 years, the rate of freedom from 
breast cancer was 85.7% in the exemestane–ovarian suppression group (hazard ratio 
for recurrence vs. tamoxifen, 0.65; 95% CI, 0.49 to 0.87).
CONCLUSIONS
Adding ovarian suppression to tamoxifen did not provide a significant benefit in 
the overall study population. However, for women who were at sufficient risk for 
recurrence to warrant adjuvant chemotherapy and who remained premenopausal, 
the addition of ovarian suppression improved disease outcomes. Further improve-
ment was seen with the use of exemestane plus ovarian suppression. (Funded by 
Pfizer and others; SOFT ClinicalTrials.gov number, NCT00066690.)
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAET BERN on March 12, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
64
34
0 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
Adjuvant Ovarian Suppression in Breast Cancer
n engl j med 372;5 nejm.org january 29, 2015 437
A djuvant endocrine therapy with tamoxifen has been recommended for premenopausal women with hormone-
receptor–positive breast cancer (positive for es-
trogen receptor, progesterone receptor, or both) 
during the past 15 years.1,2 The value of therapeu-
tic suppression of ovarian estrogen production in 
premenopausal women who receive tamoxifen is 
uncertain.3 The American Society of Clinical On-
cology endorsed guidelines recommending that 
ovarian ablation or suppression (hereafter, ovar-
ian suppression) not be added routinely to adju-
vant therapy in premenopausal women.4 Chemo-
therapy-induced ovarian suppression (amenorrhea) 
is correlated with a reduced risk of relapse5-7 but 
is less likely to be achieved in very young women. 
International consensus guidelines for breast-
cancer management in young women suggested 
that the addition of a gonadotropin-releasing 
hormone (GnRH) agonist to tamoxifen be dis-
cussed on an individualized basis.8
In 2003, the International Breast Cancer 
Study Group (IBCSG) initiated two randomized, 
phase 3 trials, the Suppression of Ovarian Func-
tion Trial (SOFT) and the Tamoxifen and Exemes-
tane Trial (TEXT), involving premenopausal 
women with hormone-receptor–positive early 
breast cancer. SOFT was designed to determine 
the value of adding ovarian suppression to 
tamoxifen and to determine the role of adjuvant 
therapy with the aromatase inhibitor exemestane 
plus ovarian suppression in premenopausal wom-
en. Here we report the results of the planned 
primary analysis in SOFT 9 comparing adjuvant 
tamoxifen plus ovarian suppression with tamoxi-
fen alone after a median follow-up of 67 months.
ME THODS
PATIENTS
The trial was designed to evaluate adjuvant endo-
crine therapy in women who remained premeno-
pausal after the completion of adjuvant or neo-
adjuvant chemotherapy and in premenopausal 
women for whom adjuvant tamoxifen alone was 
considered suitable treatment. Eligibility criteria 
included documented premenopausal status, oper-
able breast cancer, and tumor that expressed es-
trogen or progesterone receptors in at least 10% of 
the cells (see the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org).
Patients had to have undergone either a total 
mastectomy with subsequent optional radiother-
apy or breast-conserving surgery with subsequent 
radiotherapy. Either axillary dissection or a senti-
nel-node biopsy was required. Patients who had 
not received chemotherapy underwent random-
ization within 12 weeks after definitive surgery. 
Patients who received chemotherapy before ran-
domization and remained premenopausal were 
enrolled within 8 months after completing che-
motherapy, once a premenopausal estradiol level 
was confirmed by a local laboratory. Patients 
were allowed to receive adjuvant oral endocrine 
therapy before randomization.
STUDY DESIGN
Women were randomly assigned to receive oral 
tamoxifen at a dose of 20 mg daily, tamoxifen 
plus ovarian suppression, or oral exemestane 
(Aromasin, Pfizer) at a dose of 25 mg daily plus 
ovarian suppression. Treatment was for 5 years 
from the date of randomization, according to the 
study protocol, available at NEJM.org. Ovarian 
suppression was achieved by choice of triptorelin 
(Decapeptyl Depot [triptorelin acetate], Ipsen; or 
Trelstar Depot [triptorelin pamoate], Debio) at a 
dose of 3.75 mg administered by means of intra-
muscular injection every 28 days, bilateral oopho-
rectomy, or bilateral ovarian irradiation. Patients 
receiving triptorelin could subsequently opt to 
undergo oophorectomy or irradiation. Random-
ization was performed by means of the IBCSG 
Internet-based system and was stratified accord-
ing to prior chemotherapy (yes vs. no), lymph-
node status (positive vs. negative), and intended 
initial method of ovarian suppression, if as-
signed. The assessments of the patients and the 
recording of adverse events followed a regular 
schedule (see the Supplementary Appendix).
The primary end point was disease-free sur-
vival, defined as the time from randomization to 
the first appearance of one of the following: re-
currence of invasive breast cancer (local, regional, 
or distant), invasive contralateral breast cancer, 
second (nonbreast) invasive cancer, or death 
without recurrence or second cancer. Secondary 
end points included the interval without breast 
cancer, defined as the time from randomization 
to the recurrence of invasive breast cancer (local, 
regional, or distant) or invasive contralateral 
breast cancer; the interval from randomization 
to the recurrence of breast cancer at a distant 
site; and overall survival, defined as the time 
from randomization to death from any cause.
The ethics committee at each participating 
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center approved the study protocol, and all the 
patients provided written informed consent. The 
IBCSG was responsible for the trial design, data 
collection, and analysis. Pfizer and Ipsen, the re-
spective manufacturers of exemestane and trip-
torelin, donated the study drugs; neither manu-
facturer imposed restrictions with respect to the 
trial data. The manuscript was written solely by 
the authors, who vouch for the data and analyses 
reported and for the fidelity of the study to the 
protocol. The steering committee (which included 
employees of Pfizer and Ipsen) reviewed the 
manuscript and made the decision to submit it 
for publication.
STATISTICAL ANALYSIS
The original statistical analysis plan for SOFT 
was to assess disease-free survival between the 
treatment groups with three pairwise compari-
sons.9 The design assumed the enrollment of 
predominantly very young women who remained 
premenopausal after chemotherapy and would 
have an expected disease-free survival rate at 5 years 
of 67% when treated with tamoxifen, on the basis 
of outcomes for patients younger than 35 years of 
age in previous trials.9 The enrolled patients were 
older and had lower-risk characteristics than an-
ticipated, and the rate of disease-free survival 
was higher than expected. A protocol amend-
ment to the analysis plan was adopted in 2011, 
designating the test of the superiority of tamoxi-
fen plus ovarian suppression over tamoxifen 
alone as the primary analysis for SOFT.9 We cal-
culated that with an estimated 186 events of dis-
ease recurrence, second invasive cancer, or death 
in the two treatment groups after a median fol-
low-up of 5 years, the study would have at least 
80%, 69%, and 52% power to detect reductions 
in risk of 33.5%, 30%, and 25%, respectively, 
with tamoxifen plus ovarian suppression versus 
tamoxifen alone, at a two-sided alpha level of 
0.05. The comparison of exemestane plus ovarian 
suppression with tamoxifen alone became a sec-
ondary objective, and the comparison of exemes-
tane plus ovarian suppression with tamoxifen 
plus ovarian suppression was analyzed by means 
of a combined analysis with the TEXT data.10
Analyses were performed according to the 
3066 Patients underwent randomization
1021 Were assigned to receive
tamoxifen
3 Withdrew consent
1018 Were included in the
intention-to-treat population
1015 Were included in the
intention-to-treat population
1014 Were included in the
intention-to-treat population
1024 Were assigned to receive
tamoxifen plus ovarian suppression
9 Withdrew consent
2033 Were included in the intention-to-
treat population for the primary analysis
1021 Were assigned to receive
exemestane plus ovarian suppression
7 Withdrew consent
Figure 1. Randomization and Primary Analysis Populations.
The flow diagram shows the intention-to-treat population of 2033 patients included in the primary analysis (shad-
ed) of tamoxifen plus ovarian suppression, as compared with tamoxifen alone, and the analogous population of pa-
tients assigned to receive exemestane plus ovarian suppression. Additional details are provided in Figure S1 in the 
Supplementary Appendix.
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intention-to-treat principle. Kaplan–Meier esti-
mates of time-to-event end points were calcu-
lated. Hypothesis tests compared the two groups 
with the use of log-rank tests, stratified accord-
ing to prior use of chemotherapy (yes vs. no) and 
lymph-node status (positive vs. negative). Strati-
fied Cox proportional-hazards regression was 
used to estimate hazard ratios and 95% confi-
dence intervals. In prespecified secondary analy-
ses, heterogeneity of the treatment effect accord-
ing to subgroup was investigated by tests of 
treatment-by-covariate interaction, and an ad-
justed hazard ratio for the treatment effect was 
estimated.
R ESULT S
STUDY POPULATION
From December 2003 through January 2011, we 
randomly assigned 1021 premenopausal women 
to tamoxifen, 1024 to tamoxifen plus ovarian 
suppression, and 1021 to exemestane plus ovari-
an suppression. After exclusions, 2033 women 
were included in the intention-to-treat popula-
tion for the primary analysis comparing tamoxi-
fen plus ovarian suppression with tamoxifen 
alone (Fig. 1, and Fig. S1 in the Supplementary 
Appendix). The median age of the patients was 
43 years (Table 1). A total of 46.7% of the pa-
Table 1. Characteristics of Patients in the Primary Analysis, Overall and According to Chemotherapy Cohort.*
Characteristic
No Chemotherapy 
(N = 949)
Prior Chemotherapy 
(N = 1084)
Overall
(N = 2033)
Age at randomization
Median — yr 46 40 43
Distribution — no. (%)
<35 yr 14 (1.5) 219 (20.2) 233 (11.5)
35–39 yr 78 (8.2) 309 (28.5) 387 (19.0)
40–49 yr 702 (74.0) 522 (48.2) 1224 (60.2)
≥50 yr 155 (16.3) 34 (3.1) 189 (9.3)
Lymph-node status — no. (%)
Negative 861 (90.7) 463 (42.7) 1324 (65.1)
Positive 88 (9.3) 621 (57.3) 709 (34.9)
Tumor size — no. (%)†
≤2 cm 806 (84.9) 526 (48.5) 1332 (65.5)
>2 cm 136 (14.3) 513 (47.3) 649 (31.9)
Tumor grade — no. (%)‡
1 389 (41.0) 151 (13.9) 540 (26.6)
2 483 (50.9) 523 (48.2) 1006 (49.5)
3 65 (6.8) 374 (34.5) 439 (21.6)
HER2-positive — no. (%) 40 (4.2) 196 (18.1) 236 (11.6)
Interval from surgery to randomization — mo
Median 1.8 8.0 3.2
Interquartile range 1.2–2.4 5.8–10.3 1.7–8.33
Endocrine therapy before randomization — no. (%)§ 47 (5.0) 475 (43.8) 522 (25.7)
* A more complete summary is provided in Table S1 in the Supplementary Appendix. Characteristics were well balanced 
according to treatment assignment (Table S2 in the Supplementary Appendix). The statistical analysis plan did not specify 
hypothesis testing regarding comparisons between these groups. HER2 denotes human epidermal growth factor receptor 2.
† Data were missing for 7 patients who did not receive chemotherapy and for 45 who had received chemotherapy previously.
‡ Data were missing for 12 patients who did not receive chemotherapy and for 36 who had received chemotherapy previously.
§ Oral endocrine therapy before randomization was allowed while premenopausal status was established or reestablished.
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tients had not received chemotherapy previously, 
and 53.3% received chemotherapy before ran-
domization and remained premenopausal. Node-
positive disease was present in 34.9% of the pa-
tients.
EFFICACY
At a median follow-up of 67 months, 299 pa-
tients (14.7%) had recurrent disease or a second 
invasive cancer or had died. The rate of disease-
free survival at 5 years was 86.6% (95% confi-
dence interval [CI], 84.2 to 88.7) among patients 
assigned to receive tamoxifen plus ovarian sup-
pression, as compared with 84.7% (95% CI, 82.2 
to 86.9) among those assigned to tamoxifen 
alone (hazard ratio for recurrence, second inva-
sive cancer, or death, 0.83; 95% CI, 0.66 to 1.04; 
P = 0.10) (Fig. 2A). A total of 58.2% of the first 
events involved distant sites, and 12.0% were sec-
ond (nonbreast) malignant conditions (Table S3 
in the Supplementary Appendix). Planned sub-
group analyses did not reveal heterogeneity of 
treatment effect across most subgroups (Fig. S2 
in the Supplementary Appendix). However, the 
subgroup of patients with human epidermal 
growth factor receptor 2–positive tumors ap-
peared to have a greater benefit with tamoxifen 
plus ovarian suppression than with tamoxifen 
alone. In the multivariable Cox proportional-haz-
ards model, with adjustment for covariates, 
tamoxifen plus ovarian suppression significantly 
reduced the hazard of recurrence, a second inva-
sive cancer, or death, as compared with tamoxi-
fen alone (hazard ratio, 0.78; 95% CI, 0.62 to 
0.98; P = 0.03) (Table S4 in the Supplementary Ap-
pendix).
At 5 years, 88.4% (95% CI, 86.1 to 90.3) of the 
patients assigned to receive tamoxifen plus ovar-
ian suppression remained free from breast can-
cer, as compared with 86.4% (95% CI, 84.0 to 
88.5) of those assigned to receive tamoxifen 
alone (hazard ratio for recurrence, 0.81; 95% CI, 
0.63 to 1.03; P = 0.09) (Fig. 3A). After adjustment 
for covariates in the multivariable Cox propor-
tional-hazards model, tamoxifen plus ovarian 
suppression reduced the hazard of breast-cancer 
recurrence, as compared with tamoxifen alone 
(hazard ratio, 0.75; 95% CI, 0.59 to 0.96; P = 0.02). 
Among patients assigned to receive exemestane 
plus ovarian suppression, 90.9% (95% CI, 88.9 to 
92.6) remained free from breast cancer at 5 years.
Recurrence of breast cancer at a distant site 
was reported in 185 patients (9.1%), with no 
significant difference between those assigned to 
tamoxifen plus ovarian suppression and those 
assigned to tamoxifen alone (hazard ratio for 
recurrence, 0.88; 95% CI, 0.66 to 1.18; P = 0.40) 
(Fig. 3B). Death was reported in 106 patients 
(5.2%); 4 patients died without a breast-cancer 
recurrence or a second invasive cancer. Overall 
survival at 5 years was 96.7% (95% CI, 95.2 to 
97.7) among patients assigned to tamoxifen plus 
ovarian suppression and 95.1% (95% CI, 93.4 to 
96.3) among those assigned to tamoxifen alone 
(hazard ratio for death, 0.74; 95% CI, 0.51 to 
1.09; P = 0.13) (Fig. 2B).
Among patients who did not receive chemo-
therapy, more than 95% remained free from 
breast cancer at 5 years in each group (Fig. 3C), 
with few distant recurrences (Fig. 3D), and 
32.9% of first events (a second invasive cancer or 
death) were not related to breast cancer (Table 
S3 in the Supplementary Appendix). Most recur-
rences of breast cancer were in patients who 
remained premenopausal after receiving chemo-
Figure 2 (facing page). Primary Analysis Comparisons 
of Tamoxifen plus Ovarian Suppression (OS) with 
Tamoxifen Alone.
Panel A shows Kaplan–Meier estimates of disease-free 
survival, and Panel B shows the results of the Cox pro-
portional-hazards models for the comparisons of dis-
ease-free survival, freedom from recurrence of breast 
cancer, freedom from recurrence of breast cancer at a 
distant site, and overall survival, according to treat-
ment group, among all the patients and according to 
chemotherapy cohort. The solid vertical lines at 0.83, 
0.81, 0.88, and 0.74 indicate the overall hazard-ratio 
 estimates for the four end points, respectively. In the 
analysis of disease-free survival, the hazard ratio is for 
breast-cancer recurrence, a second invasive cancer, or 
death. In the analyses of freedom from breast cancer 
and freedom from recurrence of breast cancer at a dis-
tant site, the hazard ratios are for recurrence. In the 
overall survival analysis, the hazard ratio is for death. 
The P value for the comparison among all patients was 
obtained by means of a stratified log-rank test; the P value 
for the assessment of treatment-effect heterogeneity 
according to chemotherapy cohort was calculated by 
means of a test of treatment by chemotherapy cohort 
interaction from a stratified Cox proportional-hazards 
model. The x axis is scaled according to the natural 
logarithm of the hazard ratio. The size of the squares 
is inversely proportional to the standard error of the 
hazard ratio. The median follow-up was 67 months.
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therapy (Fig. 3E). In this cohort, the rate of 
freedom from breast cancer at 5 years was 82.5% 
(95% CI, 78.8 to 85.6) among those assigned to 
receive tamoxifen plus ovarian suppression and 
78.0% (95% CI, 74.0 to 81.5) among those as-
signed to receive tamoxifen alone (hazard ratio 
for recurrence, 0.78; 95% CI, 0.60 to 1.02). In the 
chemotherapy cohort, among patients assigned 
0.50 1.00 4.002.00
Tamoxifen
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to exemestane plus ovarian suppression, 85.7% 
(95% CI, 82.3 to 88.5) remained free from breast 
cancer at 5 years (Fig. 3E).
Most recurrences of breast cancer at a distant 
site occurred in the patients who had received 
chemotherapy previously. The rates of freedom 
from distant recurrence at 5 years in this cohort 
were as follows: 83.6% among patients assigned 
to tamoxifen alone, 84.8% among those assigned 
to tamoxifen plus ovarian suppression, and 87.8% 
among those assigned to exemestane plus ovar-
ian suppression (Fig. 3F).
More than 90% of the deaths occurred in pa-
tients who had received chemotherapy previously. 
Overall survival at 5 years in the chemotherapy 
cohort was 94.5% (95% CI, 92.0 to 96.2) among 
patients assigned to tamoxifen plus ovarian sup-
pression, as compared with 90.9% (95% CI, 87.9 
to 93.2) among those assigned to tamoxifen 
alone (hazard ratio for death, 0.64; 95% CI, 0.42 
to 0.96) (Fig. 2B, and Fig. S5 in the Supplemen-
tary Appendix).
A total of 350 women younger than 35 years 
of age participated in the trial, 233 of whom 
were included in the primary analysis. Among 
these women, the rate of freedom from breast 
cancer at 5 years was 67.7% (95% CI, 57.3 to 
76.0) for patients assigned to tamoxifen alone, 
78.9% (95% CI, 69.8 to 85.5) for those assigned 
to tamoxifen plus ovarian suppression, and 
83.4% (95% CI, 74.9 to 89.3) for those assigned 
to exemestane plus ovarian suppression. In this 
very young subgroup, 94.0% of the patients had 
received chemotherapy previously.
TREATMENT AND ADVERSE EVENTS
At a median follow-up of 67 months, 25.8% of 
the patients were continuing to receive some or 
all of the protocol-assigned treatment. Tamoxi-
fen was discontinued early, with or without the 
substitution of alternative endocrine therapy, in 
16.7% of the tamoxifen–ovarian suppression 
group and 21.7% of the tamoxifen group (Table 
S5 in the Supplementary Appendix). Rates of 
nonadherence with ovarian suppression were 
5.0%, 9.2%, 14.9%, 18.3%, and 21.9% at 0.5, 1, 2, 
3, and 4 years after randomization, respectively. 
Among patients assigned to ovarian suppression, 
it was achieved entirely through administration 
of the GnRH agonist triptorelin in 80.7% of the 
patients.
Targeted adverse events of grade 3 or higher 
were reported in 31.3% of the patients assigned 
to receive tamoxifen plus ovarian suppression, 
as compared with 23.7% of those assigned to 
receive tamoxifen alone (Table 2, and Table S6 in 
the Supplementary Appendix). Hot flushes, sweat-
ing, decreased libido, vaginal dryness, insomnia, 
depression, musculoskeletal symptoms, hyperten-
sion, and glucose intolerance (diabetes) were re-
ported more frequently in the tamoxifen–ovarian 
suppression group than in the tamoxifen group. 
Osteoporosis as defined by a T score of less than 
−2.5 was reported in 5.8% of the patients as-
signed to tamoxifen plus ovarian suppression and 
in 3.5% of those assigned to tamoxifen alone.
DISCUSSION
The results of SOFT show that, considering the 
entire population of patients who underwent 
randomization, the addition of ovarian suppres-
sion to adjuvant tamoxifen did not significantly 
improve disease-free survival. However, SOFT in-
vestigated ovarian suppression in two distinct 
patient cohorts. The first cohort included 949 
premenopausal women for whom adjuvant tamox-
ifen without chemotherapy was considered to be 
suitable treatment. These patients were predomi-
nantly older than 40 years of age, had small, 
node-negative tumors of low to intermediate 
grade, and had excellent outcomes with tamoxi-
fen alone after a median follow-up of 67 months. 
The findings in this cohort do not currently in-
form us about the clinical relevance of ovarian 
suppression because one third of the first events 
were not related to breast cancer, freedom from 
recurrence exceeded 95% at 5 years, and addi-
Figure 3 (facing page). Kaplan–Meier Estimates of 
 Freedom from  Recurrence of Breast Cancer and Freedom 
from the  Recurrence of Breast Cancer at a Distant Site 
after a Median Follow-up of 67 Months, According to 
Treatment Assignment.
The estimates for the primary analysis population and 
the exemestane–ovarian suppression group are sum-
marized for all patients (Panels A and B) and according 
to chemotherapy cohort (Panels C through F). The 5-year 
values are based on Kaplan–Meier estimates of the time 
to an event. In the analyses of freedom from recurrence 
of breast cancer and freedom from recurrence of breast 
cancer at a distant site, the hazard ratios are for recur-
rence of breast cancer and recurrence of breast cancer 
at a distant site, respectively.
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tional recurrences are anticipated with further 
follow-up.
By contrast, the second cohort included 1084 
women who remained premenopausal after com-
pleting chemotherapy, as shown by estradiol 
measurement regardless of menses. The clinico-
pathological features that warranted prior che-
motherapy use12 and the younger age of the 
women who remained premenopausal after che-
motherapy (median age, 40 years) contributed to 
the higher risk of recurrence in this cohort than 
in the cohort that had not received chemother-
apy. With a median of 67 months of follow-up, 
the number of breast-cancer recurrences ob-
served was large enough to indicate that includ-
ing ovarian suppression as a component of adju-
vant therapy can meaningfully reduce recurrences 
in this cohort (Fig. 3E).
For women with ovarian estrogen production 
after chemotherapy, we had hypothesized that 
therapeutic ovarian suppression would provide a 
benefit similar to that observed with chemother-
apy-induced amenorrhea.5-7 Resilience of ovarian 
function to chemotherapy correlates with young-
er age. Chemotherapy-induced ovarian suppres-
sion is common in older premenopausal women 
and is associated with improved breast-cancer 
outcomes.5-7 The SOFT design for the chemo-
therapy cohort targeted younger patients by man-
dating that only women who remained premeno-
pausal or reverted to premenopausal status 
could be enrolled. Previous trials evaluating 
ovarian suppression were confounded by the 
inclusion of women who became permanently 
postmenopausal from chemotherapy or who had 
an unknown or negative hormone-receptor sta-
tus; these trials also lacked a 5-year tamoxifen 
control group.13-15
When SOFT was planned, it was hypothesized 
that tamoxifen plus ovarian suppression would 
reduce the relative risk of breast-cancer recur-
rence, a second invasive cancer, or death by 25%, 
as compared with tamoxifen alone, and further-
more, that exemestane plus ovarian suppression 
would reduce the relative risk by 25%, as com-
pared with tamoxifen plus ovarian suppression. 
After adjustment for covariates in the multivari-
able Cox model, tamoxifen plus ovarian suppres-
sion resulted in a 22% reduction in the relative 
risk of breast-cancer recurrence, a second inva-
sive cancer, or death (P = 0.03) and a 25% reduc-
tion in the relative risk of breast-cancer recur-T
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rence, as compared with tamoxifen alone. After 
a protocol amendment, the comparison of ex-
emestane plus ovarian suppression with tamoxi-
fen plus ovarian suppression, on the basis of a 
combined analysis with TEXT, showed a 28% 
reduction in the relative risk of breast-cancer 
recurrence, a second invasive cancer, or death 
and a 34% reduction in the relative risk of breast-
cancer recurrence in the exemestane–ovarian 
suppression group (P<0.001).10
Overall, tamoxifen plus ovarian suppression 
resulted in an absolute improvement of 2.0 per-
centage points, as compared with tamoxifen 
alone, in the proportion of patients without re-
current breast cancer at 5 years. In the higher-
risk cohort of patients who remained premeno-
pausal after chemotherapy, tamoxifen plus ovarian 
suppression resulted in an absolute improvement 
of 4.5 percentage points, as compared with 
tamoxifen alone, in the proportion of patients 
without recurrent breast cancer at 5 years; with 
exemestane plus ovarian suppression, the abso-
lute improvement was 7.7 percentage points, as 
compared with tamoxifen alone. These observed 
relative and absolute benefits at 5 years from 
ovarian suppression plus tamoxifen or ovarian 
suppression plus exemestane, as compared with 
tamoxifen alone, compare favorably with the 
practice-changing results of randomized trials 
of adjuvant aromatase inhibitors versus tamoxi-
fen in postmenopausal women.16
Patients who receive a diagnosis of hormone-
receptor–positive breast cancer when they are 
younger than 35 years of age are a subgroup 
considered to be at higher risk for adverse out-
comes than are older premenopausal women, on 
the basis of retrospective analyses of data from 
IBCSG and U.S. Intergroup trials.17,18 The results 
observed in this subgroup in SOFT add to the 
evidence that ovarian suppression plays an impor-
tant role in younger premenopausal patients.13-15 
Among the women younger than 35 years of age, 
breast cancer recurred within 5 years in ap-
proximately one third of the patients assigned to 
receive tamoxifen alone but in one sixth of those 
assigned to receive exemestane plus ovarian sup-
pression.
Any benefit from ovarian suppression must 
be weighed against the adverse effects. Adding 
ovarian suppression to tamoxifen resulted in 
increased adverse events — most notably, meno-
pausal symptoms, depression, and adverse 
events with possible long-term health implica-
tions such as hypertension, diabetes, and osteo-
porosis. When exemestane is combined with 
ovarian suppression, adverse sexual, musculo-
skeletal, and bone-density effects are more 
frequent than with tamoxifen plus ovarian sup-
pression.10
Longer follow-up is required, because SOFT 
is currently underpowered, and the overall sur-
vival analysis is premature after 5% of patients 
have died. The combined analysis from TEXT 
and SOFT showed that adjuvant endocrine 
therapy with ovarian suppression plus exemes-
tane is significantly more effective than ovari-
an suppression plus tamoxifen.10 The current 
analysis indicates that in a cohort selected for 
chemotherapy and persistent premenopausal 
status, ovarian suppression plus tamoxifen im-
proves outcomes, as compared with tamoxifen 
alone, with the most striking differences ob-
served among younger patients.
We conclude that adding ovarian suppression 
to tamoxifen did not provide a significant benefit 
in the overall population of premenopausal wom-
en in this trial. However, in the cohort of women 
who had a sufficient risk of recurrence to warrant 
adjuvant chemotherapy and who had premeno-
pausal estradiol levels despite chemotherapy, ovar-
ian suppression in addition to tamoxifen reduced 
the risk of breast-cancer recurrence, as compared 
with tamoxifen alone. Ovarian suppression com-
bined with an aromatase inhibitor further re-
duced the risk of recurrence, as compared with 
tamoxifen-based therapy, in this higher-risk pre-
menopausal cohort.
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